59.45
price up icon0.03%   0.02
after-market アフターアワーズ: 59.80 0.35 +0.59%
loading
前日終値:
$59.43
開ける:
$59.43
24時間の取引高:
1.14M
Relative Volume:
0.41
時価総額:
$11.42B
収益:
$2.95B
当期純損益:
$523.88M
株価収益率:
22.10
EPS:
2.69
ネットキャッシュフロー:
$620.18M
1週間 パフォーマンス:
-0.83%
1か月 パフォーマンス:
+10.32%
6か月 パフォーマンス:
+3.99%
1年 パフォーマンス:
-10.59%
1日の値動き範囲:
Value
$58.89
$59.82
1週間の範囲:
Value
$58.44
$60.58
52週間の値動き範囲:
Value
$50.76
$73.51

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
名前
Biomarin Pharmaceutical Inc
Name
セクター
Healthcare (1131)
Name
電話
(415) 506-6700
Name
住所
105 DIGITAL DRIVE, NOVATO, CA
Name
職員
3,040
Name
Twitter
Name
次回の収益日
2025-10-27
Name
最新のSEC提出書
Name
BMRN's Discussions on Twitter

BMRN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
BMRN
Biomarin Pharmaceutical Inc
59.45 11.42B 2.95B 523.88M 620.18M 2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.13 115.03B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
776.31 81.12B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
400.17 52.54B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
839.99 51.78B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
177.12 37.12B 447.02M -1.18B -906.14M -6.1812

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-12-03 ダウングレード Leerink Partners Outperform → Market Perform
2025-11-06 ダウングレード Stifel Buy → Hold
2025-09-08 開始されました H.C. Wainwright Neutral
2025-09-03 開始されました Raymond James Outperform
2025-07-03 再開されました Morgan Stanley Overweight
2025-02-24 アップグレード Oppenheimer Perform → Outperform
2024-11-15 開始されました Wolfe Research Outperform
2024-10-30 ダウングレード William Blair Outperform → Mkt Perform
2024-10-10 再開されました Raymond James Outperform
2024-08-20 アップグレード Bernstein Mkt Perform → Outperform
2024-05-17 ダウングレード Robert W. Baird Outperform → Neutral
2024-05-14 開始されました Evercore ISI Outperform
2023-11-15 開始されました Wells Fargo Overweight
2023-10-23 アップグレード Bernstein Underperform → Mkt Perform
2023-09-28 開始されました Raymond James Mkt Perform
2023-09-18 開始されました UBS Buy
2023-07-27 開始されました Scotiabank Sector Perform
2023-07-05 アップグレード BMO Capital Markets Market Perform → Outperform
2023-06-14 再開されました Credit Suisse Outperform
2023-03-21 開始されました Bernstein Underperform
2023-02-22 ダウングレード Oppenheimer Outperform → Perform
2023-02-21 開始されました Citigroup Neutral
2023-01-30 開始されました BMO Capital Markets Market Perform
2023-01-18 開始されました Canaccord Genuity Hold
2022-10-31 アップグレード Oppenheimer Perform → Outperform
2022-07-13 開始されました Cantor Fitzgerald Overweight
2022-06-13 再開されました Wedbush Neutral
2022-04-25 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-11-22 アップグレード William Blair Mkt Perform → Outperform
2021-10-07 再開されました Jefferies Buy
2021-09-09 アップグレード Stifel Hold → Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-03-04 再開されました Guggenheim Buy
2021-03-01 アップグレード Evercore ISI In-line → Outperform
2020-08-20 ダウングレード Citigroup Buy → Neutral
2020-08-20 ダウングレード William Blair Outperform → Mkt Perform
2020-08-19 ダウングレード Evercore ISI Outperform → In-line
2020-08-19 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-08-19 ダウングレード Stifel Buy → Hold
2020-07-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-07-06 繰り返されました Citigroup Buy
2020-01-28 開始されました BMO Capital Markets Market Perform
2020-01-27 開始されました BMO Capital Markets Market Perform
2020-01-24 アップグレード RBC Capital Mkts Sector Perform → Outperform
2019-11-27 アップグレード Barclays Equal Weight → Overweight
2019-11-12 開始されました SunTrust Buy
2019-10-17 再開されました BofA/Merrill Buy
2019-05-23 再開されました Citigroup Buy
2019-04-09 再開されました Raymond James Outperform
2019-01-02 ダウングレード Raymond James Outperform → Mkt Perform
2018-12-14 開始されました Wolfe Research Outperform
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-08-07 繰り返されました Stifel Buy
2018-08-03 繰り返されました Stifel Buy
すべてを表示

Biomarin Pharmaceutical Inc (BMRN) 最新ニュース

pulisher
02:27 AM

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance - FinancialContent

02:27 AM
pulisher
08:18 AM

These nine Bay Area drug makers are hurtling toward key FDA approval decisions in 2026 - The Business Journals

08:18 AM
pulisher
Jan 01, 2026

VIRGINIA RETIREMENT SYSTEMS ET Al Reduces Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Jan 01, 2026
pulisher
Jan 01, 2026

HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver - MSN

Jan 01, 2026
pulisher
Jan 01, 2026

H.C. Wainwright: BioMarin’s (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Insider Monkey

Jan 01, 2026
pulisher
Jan 01, 2026

H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Finviz

Jan 01, 2026
pulisher
Dec 31, 2025

12 Best NASDAQ Stocks to Buy in 2026 - Insider Monkey

Dec 31, 2025
pulisher
Dec 30, 2025

BioMarin Acquiring Amicus — Both Great Companies, Only One Worth Buying Now (NASDAQ:BMRN) - Seeking Alpha

Dec 30, 2025
pulisher
Dec 30, 2025

Is BioMarin Pharmaceutical Inc. (BMRN) the Ridiculously Cheap Stock to Buy Now? - Finviz

Dec 30, 2025
pulisher
Dec 30, 2025

Cwm LLC Has $8.90 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Dec 30, 2025
pulisher
Dec 30, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Dec 30, 2025
pulisher
Dec 29, 2025

BioCentury’s 2025-26 picks and predictions. Plus: BioMarin and more biotech ICYMI — a BioCentury podcast - biocentury.com

Dec 29, 2025
pulisher
Dec 29, 2025

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal - FinancialContent

Dec 29, 2025
pulisher
Dec 29, 2025

BioMarin ends development of BMN 349 AATD therapy - MSN

Dec 29, 2025
pulisher
Dec 29, 2025

BioMarin to Acquire Amicus Therapeutics for $4.8B - Contract Pharma

Dec 29, 2025
pulisher
Dec 28, 2025

Rocket Lab, Micron, And CoreWeave Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 22-Dec. 26): Are the Others in Your Portfolio?Astera Labs (NASDAQ:ALAB), BioMarin Pharmaceutical (NASDAQ:BMRN), Ciena (NYSE:CIEN), CoreWeave (NA - Benzinga

Dec 28, 2025
pulisher
Dec 27, 2025

Portfolio Update: How BioMarin Pharmaceutical Inc stock performs in weak economy2025 Earnings Impact & Long-Term Investment Growth Plans - moha.gov.vn

Dec 27, 2025
pulisher
Dec 27, 2025

Rice Hall James & Associates LLC Boosts Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Dec 27, 2025
pulisher
Dec 27, 2025

BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Pacer Advisors Inc. - MarketBeat

Dec 27, 2025
pulisher
Dec 26, 2025

BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight (NASDAQ:BMRN) - Seeking Alpha

Dec 26, 2025
pulisher
Dec 26, 2025

Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews

Dec 26, 2025
pulisher
Dec 26, 2025

Swedbank AB Buys 35,000 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Dec 26, 2025
pulisher
Dec 24, 2025

BioMarin names new chief accounting officer - MSN

Dec 24, 2025
pulisher
Dec 24, 2025

Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Tuesday? (CORRECTED) - Benzinga

Dec 24, 2025
pulisher
Dec 24, 2025

Silver Tops $70, Novo Nordisk Soars 9% On Obesity Pill ApprovalBullish (NYSE:BLSH), BioMarin Pharmaceutical (NASDAQ:BMRN) - Benzinga

Dec 24, 2025
pulisher
Dec 23, 2025

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion - New Jersey Business Magazine

Dec 23, 2025
pulisher
Dec 23, 2025

BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know - Finviz

Dec 23, 2025
pulisher
Dec 23, 2025

What's Going On With BioMarin Stock On Tuesday? - Sahm

Dec 23, 2025
pulisher
Dec 23, 2025

BioMarin Pharmaceutical (NASDAQ:BMRN) Trading 3.9% Higher on Analyst Upgrade - MarketBeat

Dec 23, 2025
pulisher
Dec 23, 2025

BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $100.00 Price Target at Truist Financial - MarketBeat

Dec 23, 2025
pulisher
Dec 22, 2025

Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition - Finviz

Dec 22, 2025
pulisher
Dec 22, 2025

Analysts grow more bullish on BioMarin Pharmaceuticals Inc. (BMRN) after Amicus acquisition - MSN

Dec 22, 2025
pulisher
Dec 22, 2025

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE) - The Globe and Mail

Dec 22, 2025
pulisher
Dec 22, 2025

Narrow-Moat BioMarin's $4.8 Billion Deal for Amicus Therapeutics Expands Rare Disease Portfolio - Morningstar

Dec 22, 2025
pulisher
Dec 22, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), Disc Medicine (IRON) and BioMarin Pharmaceutical (BMRN) - The Globe and Mail

Dec 22, 2025
pulisher
Dec 22, 2025

BioMarin (BMRN) Stock News Today: Amicus Acquisition Fallout, BMN 349 Cut, and Fresh Wall Street Price Targets (Dec. 22, 2025) - ts2.tech

Dec 22, 2025
pulisher
Dec 22, 2025

American biotech company BioMarin acquires Amicus Therapeutics for $4.8 billion - AKM.RU

Dec 22, 2025
pulisher
Dec 22, 2025

BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN) - Seeking Alpha

Dec 22, 2025
pulisher
Dec 22, 2025

BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B - sharewise.com

Dec 22, 2025
pulisher
Dec 22, 2025

7 Most Promising Gene Editing Stocks According to Analysts - Insider Monkey

Dec 22, 2025
pulisher
Dec 22, 2025

BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push - Pharmaceutical Technology

Dec 22, 2025
pulisher
Dec 22, 2025

BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement - Fierce Biotech

Dec 22, 2025
pulisher
Dec 22, 2025

BioMarin stock price target raised to $100 from $80 at Truist Securities - Investing.com UK

Dec 22, 2025
pulisher
Dec 22, 2025

BioMarin stock price target raised to $100 from $80 at Truist Securities By Investing.com - Investing.com Australia

Dec 22, 2025
pulisher
Dec 22, 2025

BioMarin drops development of liver, lung disease asset - Seeking Alpha

Dec 22, 2025
pulisher
Dec 22, 2025

Truist Securities Lifts BioMarin Pharmaceutical Price Target to $100 From $80, Maintains Buy Rating - marketscreener.com

Dec 22, 2025
pulisher
Dec 22, 2025

BioMarin ends development of BMN 349 for AATD liver disease - Investing.com

Dec 22, 2025
pulisher
Dec 22, 2025

BioMarin Ends Development of BMN 349 AATD Therapy - TipRanks

Dec 22, 2025
pulisher
Dec 22, 2025

BioMarin stock price target raised to $60 from $55 at H.C. Wainwright By Investing.com - Investing.com South Africa

Dec 22, 2025
pulisher
Dec 22, 2025

BioMarin ends development of BMN 349 for AATD liver disease By Investing.com - Investing.com UK

Dec 22, 2025
pulisher
Dec 22, 2025

BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $60.00 Price Target at HC Wainwright - MarketBeat

Dec 22, 2025

Biomarin Pharmaceutical Inc (BMRN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$38.86
price up icon 0.57%
$31.82
price up icon 3.31%
$101.42
price up icon 2.68%
$96.69
price up icon 1.57%
biotechnology ONC
$311.02
price up icon 2.37%
$177.12
price up icon 1.77%
大文字化:     |  ボリューム (24 時間):